A Key Opinion Leader is a professionally recognized person with demonstrable expertise in a medical or scientific field. In clinical research, this expertise can be incorporated into the planning, feasibility, and interpretation of a study. The term does not describe a regulatory function and must not be understood as a promotional distinction.
Role in study planning
Key Opinion Leaders can provide the sponsor with scientific advice, for example on standard of care, clinically relevant questions, suitable target populations, or practicable study procedures. Their perspective can help identify critical quality factors at an early stage, including eligibility criteria, feasibility at the trial site, the selection of meaningful endpoints, and the burden on participants. However, decisions on study design, protocol, and regulatory strategy remain with the sponsor and the respective responsible persons.
Advice must not replace the scientific independence of the study. Proposals must be assessed on the basis of the study objectives, available evidence, and regulatory requirements. The protocol remains the authoritative description of the study’s objective, design, methodology, statistics, and organization. Even a highly respected expert cannot justify any deviation from GCP, informed consent requirements, or the protection of participants.
When selecting trial sites, expertise regarding patient populations, infrastructure, and clinical procedures can be helpful. Key Opinion Leaders can identify potential sites or healthcare networks. However, the selection itself must be based on documented suitability criteria, such as experience, resources, qualifications, recruitment potential, and the ability to conduct the study in accordance with the protocol. Reputation alone is not a sufficient selection criterion.
In advisory boards, external experts provide structured advice on clearly defined scientific questions. The mandate, participants, discussion topics, compensation, and outcomes should be documented transparently. Advisory boards are not a decision-making body for the study and must not be used to conceal impermissible influence or the subsequent justification of decisions made in advance. If an expert later assumes a role as an investigator or author, responsibilities and data access must also be clearly defined.
Conflicts of interest and transparency
Professional expertise and financial or professional relationships may exist at the same time. A conflict of interest exists when an interest may influence impartiality in a specific activity or could reasonably be perceived as influencing it. Relevant relationships include, for example, employment, consultancy, holdings, research funding, work as an investigator, membership in an advisory board, or product-related compensation.
Transparency means identifying and assessing such interests before engagement and keeping them up to date throughout the collaboration. Depending on the role, measures such as disclosure, restricting the scope of duties, exclusion from certain decisions, or involving independent expertise may be necessary. The EMA requires declarations of interests from its scientific committees and experts and applies graduated restrictions. For study projects, the contractual and institutional rules are additionally decisive.
Distinction from investigator and scientific adviser
A Key Opinion Leader is not a legally defined substitute for the investigator or principal investigator. At the trial site, the investigator is responsible for conducting the clinical trial; the principal investigator leads a team of investigators at the site. These roles derive from Regulation (EU) No 536/2014 and require specifically assigned responsibilities. A KOL may be an investigator, but does not have to be.
A scientific adviser is also not automatically a Key Opinion Leader. Providing advice is a contractual task with a defined scope, whereas the term KOL describes a professional standing. For governance purposes, the actual activity is decisive: advice, trial site activities, analysis, or authorship must be documented separately and conflicts of interest must be addressed transparently.
Relevance for clinical trials
The appropriate involvement of recognized expertise can strengthen the scientific relevance and feasibility of a study. Risks arise when expert status is confused with decision-making authority or when financial relationships, data access, and publication roles remain unclear. For robust study documentation, documented selection criteria, the mandate, advice output, and procedures for managing conflicts of interest are therefore important.
Full-service CROs such as Mediconomics support the structured involvement of external expertise through documented selection processes, contracts, interest declarations, and the organization of scientific advisory boards. They coordinate interfaces with study planning, trial site selection, medical writing, and project management without assuming the independent responsibilities of the sponsor and investigator.
Compensation must be appropriate and documented.
Frequently Asked Questions (FAQ)
Is a Key Opinion Leader always the principal investigator?
No. A KOL may provide advice, work as an investigator, or have no role in conducting the study. The respective duties must be defined separately.
Why must interests be disclosed?
Disclosure makes it possible to assess potential influences and define appropriate measures to safeguard independence.
Does an advisory board decide on the protocol?
No. An advisory board provides advice. Responsibility for and approval of the study documents remain with the persons and bodies responsible for them.
Regulatory references
- Regulation (EU) No 536/2014 – roles of the investigator and principal investigator and protection of participants in clinical trials.
- ICH E8(R1) General Considerations for Clinical Studies – quality must already be considered in the study design and with the involvement of relevant perspectives.
- ICH E6(R3) Good Clinical Practice – sponsor, investigator, and service provider responsibilities.
- EMA Policy 0044 – EMA’s handling of competing interests of scientific experts.